Eton Pharmaceuticals, Inc.
NASDAQ•ETON
CEO: Mr. Sean E. Brynjelsen
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2018-11-13
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Contact Information
21925 W. Field Parkway, Suite 235, Deer Park, IL, 60010-7278, United States
847-787-7361
Market Cap
$865.32M
P/E (TTM)
-584.4
24.5
Dividend Yield
--
52W High
$35.66
52W Low
$13.09
52W Range
Rank56Top 81.7%
2.5
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data